Participating
Organizations
Centers for Disease Control and Prevention
(CDC), (http://www.cdc.gov)

Components of Participating Organizations
National Institute for Occupational Safety and Health (NIOSH), (http://www.cdc.gov/niosh/)

Title:NIOSH Support for Conferences and Scientific
Meetings (R13)

The policies, guidelines, terms, and
conditions of the HHS Centers for Disease Control and Prevention (CDC) stated
in this announcement may differ from those used by the HHS National Institutes
of Health (NIH).

Authority

This program is described in the Catalog of
Federal Domestic Assistance at http://www.cfda.gov/ and is not
subject to the intergovernmental review requirements of Executive Order 12372
or Health Systems Agency Review. Awards are made under the authorization of the
Occupational Safety and Health Act of 1970, Section
20(a) and 21(a) (29 USC 669(a) and 29 USC 670); Federal Mine Safety and Health
Act, Section 501(a), 30 USC 951(a); Section 301 of the Public Health Service
Act as amended (42 USC 241) and under Federal Regulations 42 CFR Part 52 and 45
CFR Parts 74 and 92. All awards are subject to the terms and conditions, cost
principles, and other considerations described in the HHS Grants Policy
Statement.

August 16, 2010 - IMPORTANT NOTE! NIH has eliminated the error correction window for due dates of January 25, 2011 and beyond. As of January 25, all corrections
must be complete by the due date for an application to be considered on-time. See NOT-OD-10-123.

Program
Announcement (PA) Number:PAR-10-272

NOTICE: Applications
submitted in response to this Funding Opportunity Announcement (FOA) for
Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related
(R&R) forms and the SF424 (R&R) Application Guide.

APPLICATIONS MAY NOT
BE SUBMITTED IN PAPER FORMAT.

This FOA must be read in
conjunction with the application guidelines included with this announcement in Grants.gov/Apply for Grants (hereafter called Grants.gov/Apply).

A registration process
is necessary before submission and applicants are highly encouraged to start
the process at least four (4) weeks prior to the grant submission date. See Section IV.

The National Institute for Occupational Safety
and Health (NIOSH) within the Centers for Disease Control and Prevention (CDC)
invites grant applications for conferences and scientific meetings related to occupational
safety and health.

Purpose: The purpose of the NIOSH Research Conference Grant Program (R13) is
to support high quality conferences/scientific meetings that are relevant
to its scientific mission and to the public health. A
conference/scientific meeting is defined as a gathering, symposium, seminar,
scientific meeting, workshop or any other organized, formal meeting where
persons assemble to coordinate, exchange, and disseminate information or
to explore or clarify a defined subject, problem, or area of knowledge. Applications for training only events will not be considered under
this announcement.

Funds Available and
Anticipated Number of Awards:Awards issued under this FOA are contingent upon the
availability of funds and the submission of a sufficient number of
meritorious applications.

Budget and Project Period: The total amount
awarded is expected to range between $10,000 and $20,000.
Requests for more than $20,000 (total costs) will require a prior approval letter from CDC/NIOSH.
Project periods can range between one and three years. Facilities and administrative (F&A) costs (also called indirect
costs) and pre-award costs are not allowable costs for this mechanism.

Application
Research Strategy Length: The R13 application
Research Strategy section may not exceed 6 pages, including tables, graphs,
figures, diagrams, and charts. See Table of Page Limits.

Eligible Project
Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to
carry out the proposed research are invited to work with their
institution/organization to develop an application for support.
Individuals from underrepresented racial and ethnic groups as well as
individuals with disabilities are always encouraged to apply for NIOSH support.

Number of PDs/PIs: More than one PD/PI, or multiple PDs/PIs, may be designated on the
application.

Number of
Applications: Applicants may submit more than one application,
provided they propose scientifically distinct conferences or scientific
meetings.

Resubmissions: Applicants may submit a resubmission application, but such
application must include an “Introduction” (limited to one page) addressing
the previous peer review critique (Summary Statement).

NIOSH recognizes the value of supporting high
quality scientific meetings that are relevant to its scientific mission and to
the public health. A scientific meeting is defined as a gathering, symposium,
seminar, conference, workshop or any other organized, formal meeting where
persons assemble to coordinate, exchange, and disseminate information or to
explore or clarify a defined subject, problem, or area of knowledge. Support of
such meetings is contingent on fiscal and programmatic interests and priorities
of NIOSH (see http://www.cdc.gov/niosh/ and http://www.cdc.gov/niosh/programs/. While training is often a part of conferences
or scientific meetings, applications for training only events will not be
considered under this announcement.

This FOA will use the Scientific Conference/Meeting
(R13) grant award mechanism. Under the R13 mechanism, the applicant will be
solely responsible for planning, directing, and executing the proposed project.
Multiple year awards may be made to a permanently sponsoring organization for
conferences held annually on a recurring topic. The total project period for an
application requesting support may not exceed three years.

Applicants must complete and submit a
detailed categorical request using the Research & Related Budget component.

2. Funds
Available

Because the nature and scope of the proposed
research will vary from application to application, it is anticipated that the
size and duration of each award will also vary. Although the NIOSH financial
plans provide support for this program, awards pursuant to this funding
opportunity are contingent upon the availability of funds.

Awards may range up to $20,000 (total costs). Applicants
requesting more than $20,000 (total costs) must obtain written prior approval
from the NIOSH Scientific Program Official assigned to this announcement. If an
applicant requests a funding amount greater than the ceiling of the award range
without providing the required letter of approval from NIOSH, the application will
be considered non-responsive, and it will not enter into the review process.
HHS/CDC will notify the applicant that the application did not meet the
submission requirements. NOTE: the letter approving submission of an
application exceeding the $20,000 total costs limit does not assure funding.

HHS
grants policies as described in both the HHS Grants Policy Statement, will
apply to the applications submitted and awards made in response to this FOA.

State and local governments or their Bona Fide Agents
(this includes the District of Columbia, the Commonwealth of Puerto Rico,
the Virgin Islands, the Commonwealth of the Northern Marianna Islands,
American Samoa, Guam, the Federated States of Micronesia, the Republic of
the Marshall Islands, and the Republic of Palau)

Political subdivision of States (in consultation with
States)

Foreign institutions are
not eligible to apply.

A Bona Fide Agent is an agency/organization identified by
the state as eligible to submit an application under the state eligibility in
lieu of a state application. If you are applying as a bona fide agent of
a state or local government, you must provide a letter from the state or local
government as documentation of your status. Include this document in the Research and Related Other
Project Information in section 11, Other Attachments.

Domestic
institutions or organizations, including established scientific or professional
societies, are eligible to apply for conference support. Both domestic and
international conferences may be supported; however, an international
conference can be supported only through the U.S. representative organization
of an established international scientific or professional society. An
individual is not eligible to receive a grant in support of a conference.

1.B.
Eligible Individuals

Any individual(s) with the skills, knowledge,
and resources necessary to carry out the proposed research as the PD/PI is
invited to work with his/her organization to develop an application for
support. Individuals from underrepresented racial and ethnic groups as well as
individuals with disabilities are always encouraged to apply for support.

More than one PD/PI, or multiple PDs/PIs, may
be designated on the application for projects that require a “team science”
approach and therefore clearly do not fit the single-PD/PI model. Additional
information on the implementation plans and policies and procedures to formally
allow more than one PD/PI on individual research projects is available at http://grants.nih.gov/grants/multi_pi. All PDs/PIs must be registered in the NIH eRA
Commons prior to the submission of the application (see http://era.nih.gov/ElectronicReceipt/preparing.htm for instructions).

The decision of whether to apply for a single
PD/PI or multiple PD/PI grant is the responsibility of the investigators and
applicant organizations and should be determined by the scientific goals of the
project. Applications for multiple PD/PI grants will require additional
information, as outlined in the instructions below. When considering the multiple
PD/PI option, please be aware that the structure and governance of the PD/PI
leadership team as well as the knowledge, skills and experience of the
individual PDs/PIs will be factored into the assessment of the overall
scientific merit of the application. Multiple PDs/PIs on a project share the
authority and responsibility for leading and directing the project,
intellectually and logistically. Each PD/PI is responsible and accountable
to the grantee organization, or, as appropriate, to a collaborating
organization, for the proper conduct of the project or program, including the
submission of required reports. For further information on multiple PDs/PIs,
please seehttp://grants.nih.gov/grants/multi_pi.

Conference grant applications are reviewed
three times per year (Feb/June/Oct). NIOSH will only accept applications with
at least an eight-month span of time between a standard application submission
date (April/Aug/Dec) and the date of the scientific meeting. Interested
applicants should refer to the respective Standard Submission Dates and Earliest
Meeting Dates listed below:

Standard Submission Date

Earliest Meeting Date

April 12

December 12 of same year

August 12

April 12 of following year

Dec 12

August 12 of following year

Number of Applications. Applicants may submit more than one application, provided each
application is scientifically distinct.

Resubmissions. Applicants may submit a resubmission application, but such application
must include an Introduction addressing the previous peer review critique
(Summary Statement).

To download a SF424 (R&R) Application
Package and SF424 (R&R) Application Instructions for completing the SF424
(R&R) forms for this FOA, link to Grants.gov/Apply and follow the directions provided on that Web site.

Registration:

Appropriate
registrations with Grants.gov and eRA Commons must be completed on or before
the due date in order to successfully submit an application. Several of the
steps of the registration process could take four weeks or more. Therefore,
applicants should immediately check with their business official to determine
whether their organization/institution is already registered with both Grants.gov and the Commons. All registrations must be complete by
the submission deadline for the application to be considered “on-time” (see
3.C.1 for more information about on-time submission).

A one-time registration is required for
institutions/organizations at the following:

The individual(s) designated as PDs/PIs on the application
must be registered also in the NIH eRA Commons. In the case of multiple
PDs/PIs, all PDs/PIs must be registered and be assigned
the PI role in the eRA Commons prior to the submission of the application.

Each
PD/PI must hold a PD/PI account in the Commons. Applicants should not share a
Commons account for both an Authorized Organization Representative/Signing
Official (AOR/SO) role and a PD/PI role; however, if they have both a PD/PI
role and an Internet Assisted Review (IAR) role, both roles should exist under
one Commons account.

When multiple
PDs/PIs are proposed, all PDs/PIs at the applicant organization must be
affiliated with that organization. PDs/PIs located at another institution
need not be affiliated with the applicant organization, but must be affiliated
with their own organization to be able to access the Commons.

This
registration/affiliation must be done by the AOR/SO or his/her designee who is
already registered in the Commons.

Both the PD(s)/PI(s) and
AOR/SO need separate accounts in the NIH eRA Commons since both are authorized
to view the application image.

Note: The registration
process is not sequential. Applicants should begin the registration processes
for both Grants.gov and eRA Commons as soon as their organization has obtained
a DUNS number. Only one DUNS number is required and the same DUNS number must
be referenced when completing Grants.gov registration, eRA Commons registration
and the SF424 (R&R) forms.

Applicants must download the SF424 (R&R)
application forms and SF424 (R&R) Application Guide for this FOA through Grants.gov/Apply.

Note: Only the forms package directly attached
to a specific FOA can be used. You will not be able to use any other SF424
(R&R) forms (e.g., sample forms, forms from another FOA); although some of
the "Attachment" files may be useable for more than one FOA.

The SF424 (R&R) Application Guide is critical to
submitting a complete and accurate application to NIH. Some fields within the
SF424 (R&R) application components, although not marked as mandatory, are
required by NIH (e.g., the “Credential” log-in field of the “Research &
Related Senior/Key Person Profile” component must contain the PD/PI’s assigned
eRA Commons User ID). Agency-specific instructions for such fields are
clearly identified in the Application Guide. For additional information, see
“Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.”

The SF424 (R&R) application has several components.
Some components are required, others are optional. The forms package associated
with this FOA in Grants.gov/APPLY includes all applicable components, required and
optional. A completed application in response to this FOA includes the data in
the following components:

When
multiple PDs/PIs are proposed, HHS/CDC requires one PD/PI to be designated as
the "Contact” PI, who will be responsible for all communication between
the PDs/PIs and the HHS/CDC, for assembling the application materials outlined
below, and for coordinating progress reports for the project. The contact PD/PI
must meet all eligibility requirements for PD/PI status in the same way as
other PDs/PIs, but has no other special roles or responsibilities within the
project team beyond those mentioned above.

Information
for the Contact PD/PI should be entered on the SF424 (R&R) Cover
component. All other PDs/PIs should be listed in the Research &
Related Senior/Key Person component and assigned the project role of
“PD/PI.” Please remember that all PDs/PIs must be registered in the eRA Commons prior to application submission. The Commons ID of each PD/PI must be included in the
“Credential” field of the Research & Related Senior/Key Person
component. Failure to include this data field will cause the application
to be rejected.

Multiple PD/PI Leadership Plan:For
applications designating multiple PDs/PIs, the section of the Research Plan,
entitled “Multiple PD/PI Leadership Plan”, must be included. A rationale for
choosing a multiple PD/PI approach should be described. The governance and
organizational structure of the leadership team and the research project should
be described, and should include communication plans, process for making
decisions on scientific direction, and procedures for resolving
conflicts. The roles and administrative, technical, and scientific
responsibilities for the project or program should be delineated for the
PDs/PIs and other collaborators.

If
budget allocation is planned, the distribution of resources to specific
components of the project or the individual PDs/PIs should be delineated in the
Leadership Plan. In the event of an award, the requested allocations may be
reflected in a footnote on the Notice of Award (NoA).

Applications
Involving a Single Institution

When all PDs/PIs are within a single
institution, follow the instructions contained in the SF424 (R&R)
Application Guide.

Applications
Involving Multiple Institutions

When multiple institutions are involved, one
institution must be designated as the prime institution and funding for the
other institution(s) must be requested via a subcontract to be administered by
the prime institution. When submitting a detailed budget, the prime institution
should submit its budget using the Research & Related Budget
component. All other institutions should have their individual budgets
attached separately to the Research & Related Subaward Budget Attachment(s)
Form. See Section 4.8 of the SF424 (R&R) Application Guide for further
instruction regarding the use of the subaward budget form.

Prospective applicants are asked to submit a
letter of intent that includes the following information:

Descriptive title of
proposed conference or scientific meeting.

Name, address, and
telephone number of the Principal Investigator

Names of other key
personnel

Participating
institutions

Number and title of
this funding opportunity

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent
application, the information that it contains allows NIOSH Review staff to
estimate the potential review workload and plan the review.

To submit an application in response to this FOA,
applicants should access this FOA via http://www.grants.gov/applicants/apply_for_grants.jsp and follow Steps 1-4. Note: Applications must only be
submitted electronically. PAPER APPLICATIONS WILL NOT BE ACCEPTED. All attachments must be provided
in PDF format, filenames must be included with no spaces or special characters,
and a .pdf extension must be used.

Applications may be submitted on or
after the opening date and must be successfully received by Grants.gov
no later than 5:00 p.m. local time (of the applicant institution/organization) on the application submission/receipt date(s). (See Section IV.3.A. for all dates.) If an application is not submitted by the receipt date(s) and time, the
application may be delayed in the review process or not reviewed. All applications must
meet the following criteria to be considered “on-time”:

All
registrations must be complete prior to the submission deadline.

The
application must receive a Grants.gov tracking number and timestamp (or eRA
help desk ticket confirming a system issue preventing submission) by 5:00 p.m.
local time on the submission deadline date.

Any
system identified errors/warnings must be corrected and the submission process
completed within the “error correction window.”

Submission to Grants.gov is not the last step –
applicants must follow their application through to the eRA Commons to check
for errors and warnings and view their assembled application!

3.C.2 Two
Day Window to Correct eRA Identified Errors/Warnings

IMPORTANT NOTE! NIH has eliminated the error correction window for due dates of January 25, 2011 and beyond.
As of January 25, all corrections must be complete by the due date for an application to be considered on-time. See
NOT-OD-10-123.

Once an application package has been successfully
submitted through Grants.gov, NIH (who receives applications on behalf of
NIOSH) provides applicants a two day error correction window to correct any eRA
identified errors or warnings before a final assembled application
is created in the eRA Commons. The standard error correction window is two (2)
business days, beginning the day after the submission deadline and excluding
weekends and standard federal holidays. All errors must be corrected to
successfully complete the submission process. Warnings will not prevent the
application from completing the submission process.

Please note that the following caveats
apply:

Initial
application submission must be “on-time.”

The
AOR/institutions is expected to enforce that application changes made within
the error correction window are restricted to those necessary to address
system-identified errors/warnings. NIH may reject any application that includes
additional changes.

Proof
of “on-time” submission (e.g., Grants.gov timestamp and tracking number) and
description of all changes made within the window must be documented in the PHS
398 Cover Letter component of the application.

3.C.3 Viewing an Application in the eRA Commons

Once any eRA identified errors have been
addressed and the assembled application has been created in the eRA Commons, the PD/PI and the
Authorized Organization Representative/Signing Official (AOR/SO) have two
weekdays (Monday – Friday, excluding Federal holidays) to view the assembled
application before
it automatically moves forward to NIH for further processing.

If everything is
acceptable, no further action is necessary. The application will
automatically move forward for processing by the Division of Receipt and
Referral, Center for Scientific Review, NIH, after two business days.

Prior to the
submission deadline, the AOR/SO can “Reject” the assembled application and
submit a changed/corrected application within the two-day viewing window.
This option should be used if it is determined that some part of the
application was lost or did not transfer correctly during the submission
process, the AOR/SO will have the option to “Reject” the application and
submit a Changed/Corrected application. In these
cases, please contact the eRA Help Desk to ensure that the issues are
addressed and corrected. Once rejected, applicants should follow the
instructions for correcting errors in Section 2.12 of the SF 424 (R&R)
application guide, including the requirement for cover letters on late
applications. The “Reject” feature should also be used if you
determine that warnings are applicable to your application and need to be
addressed now. Remember, warnings do not stop further application
processing. If an application submission results in warnings (but no
errors), it will automatically move forward after two weekdays if no action
is taken. Some warnings may need to be addressed later in the process.

If the two day
window falls after the submission deadline, the AOR/SO will have the
option to “Reject” the application if, due to an eRA Commons or Grants.gov
system issue, the application does not correctly reflect the submitted
application package (e.g., some part of the application was lost or didn’t
transfer correctly during the submission process). The AOR/SO should first
contact the eRA
Commons Helpdesk to confirm the
system error, document the issue, and determine the best course of action.
NIH will not penalize the applicant for an eRA Commons or Grants.gov
system issue.

If the AOR/SO
chooses to “Reject” the image after the submission deadline for a reason
other than an eRA Commons or Grants.gov system failure, a
changed/corrected application still can be submitted but it will be
subject to the NIH late policy guidelines and may not be accepted. The reason for this delay
should be explained in the cover letter attachment.

Both the AOR/SO and
PD/PI will receive e-mail notifications when the application is rejected
or the application automatically moves forward in the process after two
days.

Upon receipt, applications will be evaluated
for completeness by the Center for Scientific Review, NIH. Incomplete
applications will not be reviewed.

There will be an acknowledgement of receipt of
applications from Grants.gov and the Commons. The
submitting AOR receives the Grants.gov acknowledgments. The AOR and the PI
receive Commons acknowledgments. Information related to the assignment of an
application to a Scientific Review Group is also in the Commons.

Note: Since email can be unreliable, it is the
responsibility of the applicant to check periodically on their application
status in the Commons.

NIOSH will not accept any application in
response to this FOA that is essentially the same as one currently pending
initial merit review unless the applicant withdraws the pending application. NIOSH
will not accept any application that is essentially the same as one already
reviewed. However, NIOSH will accept a resubmission application, but such
application must include an Introduction addressing the critique from the
previous review.

All CDC/NIOSH awards are subject to the terms
and conditions, cost principles, and other considerations described in the HHS Grants Policy Statement.

Allowable Costs: Salaries in proportion to the time or effort spent directly
on the meeting; rental of necessary equipment; travel and per diem or
subsistence allowances; supplies needed for conduct of the meeting, only
if received for use during the budget period; conference services;
publication costs; registration fees; speakers' fees.

Applications with total costs exceeding $20,000 need advance approval from
NIOSH. Such approval should be requested early in the process, and no later
than two months before the receipt date. The letter from NIOSH documenting
advance approval to request more than $20,000 (total costs) must be submitted
with the application. Attach the letter as part of the PHS 398 Cover Letter
component (PDF). If an application is received without an approval letter, it
will not be accepted for review. Note that advance approval to submit an
application does not guarantee funding. Resubmission and renewal applications
will be accepted.

The following instructions are to be used in conjunction with the
SF424 (R&R) Application Guide accompanying the SF424 (R&R) application
form:

SF424 (R&R) Cover Component: Enter the title of the
scientific conference or scientific meeting in the
Descriptive Title of Applicant’s Project field of the SF424 Cover component.

Research and Related Project/Performance Site Locations: Enter the
site of the conference or meeting as the Performance Site.

Research and Related Budget: The NIOSH conference award
contact should be consulted for guidance regarding any NIOSH specific budget
requirements. Enter the direct costs requested. Provide a narrative
justification for each proposed personnel position, including role and proposed
level of effort. Include information regarding efforts to obtain funding for
this conference/meeting from other sources. If the proposed conference is one
of an ongoing series, please include a justification for why
NIOSH support is required to continue the series, in addition to registration
fees and/or other sources of support.

PHS 398 Checklist Component: The checklist is required;
however, no information regarding facilities and administrative (F&A) costs
(also called indirect costs) should be included as these are not allowable
costs for this mechanism

The applicant organization must include its DUNS number
in its Organization Profile in the eRA Commons. This DUNS number must match the
DUNS number provided at CCR registration with Grants.gov. For additional information, see
“Frequently Asked Questions – Application Guide, Electronic Submission
of Grant Applications.”

PHS398 Research Plan Component Sections

All
application instructions outlined in the SF424 (R&R) Application Guide are
to be followed, incorporating "Just-in-Time"
information concepts, and with the following additional requirements:

Introduction
(required for a resubmission or revision application) is limited to 1
page.

Research
Strategy, including tables, graphs, figures, diagrams, and charts, is
limited to 6 pages. Note that this section will be called “Research
Strategy” in the system-generated Table of Contents. Do not complete
the Human Subjects sections of the PHS 398 Research Plan.

Specific
Aims is required on the PHS 398
Research Plan and limited to one page

In the “Conference Plan” section of the
application (uploaded as the Research Strategy attachment), describe
the objectives, specific program, and logistical arrangements for the meeting.
Describe the format and list the agenda and speakers, including the principal
topics to be covered, problems to be addressed, and developments or
contributions the conference/meeting might stimulate. Provide a detailed
justification for the conference/meeting, including the scientific need,
timeliness, and usefulness of the conference/meeting to the scientific
community. Describe the composition and role of the organizing committee, and
provide the names and credentials of key participants in the
conference/meeting, including the basis for their selection and documentation
of their agreement to participate.

Describe plans for the appropriate involvement of women, minorities,
and persons with disabilities in the planning and implementation of, and
participation in, the proposed conference/meeting. Describe
plans to identify resources for child care and other types of family care at
the conference site to allow individuals with family care responsibilities to
attend. That information should allow attendees to make arrangements for family
care as needed. Estimate the expected size and composition of the audience, as
well as the method of selection. Describe plans for publicizing the
conference/meeting to all interested participants and for publishing the
proceedings (with the latter possibility not being required). Identify related conferences
or meetings held on the subject during the past 3 years and how the proposed
conference or meeting is similar to, and/or different from these, and why it is
still necessary and useful. If this is one of a series of periodic
conferences/meetings held by a permanent sponsoring organization, briefly
describe and evaluate the last conference/meeting in the series.

Applications requesting multiple years of support must provide the
following additional information for each future year requested, in as much
detail as possible: meeting topic(s); tentative dates, locations, and
participants; and contingency plans for future meetings dependent upon, for
example, the outcome of the first year’s conference/meeting or developments in
the field.

A critical part of the application for CDC/NIOSH support of
conferences/meetings is documentation of appropriate representation of women,
racial/ethnic minorities, persons with disabilities, and other individuals who
have been traditionally underrepresented in science. Attendance
for some individuals will be dependent on the availability of resources for
family care. A broad cross section of individuals must be included in all
aspects of planning, organization, and implementation of CDC/NIOSH-sponsored
and/or supported conferences/meetings. “Appropriate representation” means
representation based on the availability of these scientists from these groups
known to be working in a particular field of biomedical or behavioral research.
If appropriate representation is not apparent, no award will be issued until
program staff members are assured of concerted recruitment efforts. Organizers
of scientific conferences/meetings must document compliance with the Guidelines
for Inclusion of Women, Minorities, and Persons with Disabilities in Scientific
Meetings Supported by the CDC/NIOSH.

Appendix Materials

The
appendix is limited to announcements and reports of previous
conferences/meetings under the same sponsorship. No other information or
material should be submitted as appendices.

Do
not use the Appendix to circumvent the page limitations. An application that
does not comply with the required page limitations may be delayed in the review
process.

Only the
review criteria described below will be considered in the review process.

2. Review and Selection Process

Review Process

Applications
that are complete will be evaluated for scientific and technical merit by an
appropriate scientific review group in accordance with CDC/NIOSH peer review
procedures using the review criteria stated below.

As part of the initial merit review, all
applications will:

Undergo a selection
process in which all applications will be discussed and assigned an impact/priority
score

Receive a written
critique; and

Receive a second
level of review by the NIOSH Secondary Review Committee

The mission of CDC/NIOSH is to
promote health and quality of life by preventing and controlling disease,
injury, and disability. The
goal of the NIOSH research and training programs is to identify the risks and
conditions that are associated with occupational diseases and injuries, to
explore methods for reducing risks and for preventing or minimizing exposure to
hazardous conditions in the workplace, and to translate significant scientific
findings into prevention practices and products that will effectively reduce
work-related illnesses and injuries. The scientific review group will address
and consider each of the review criteria in assigning the application's overall
score, weighting them as appropriate for each application.

Overall Impact

Reviewers will provide an overall impact/priority
score to reflect their assessment of the likelihood for the project to exert a
sustained, powerful influence on the research field(s) involved, in
consideration of the following five scored review criteria, and additional
review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the five
review criteria below in the determination of scientific and technical merit,
and give a separate score for each. An application does not need to be strong
in all categories to be judged likely to have major scientific impact. For
example, a project that by its nature is not innovative may be essential to
advance a field.

Significance. Does the conference/scientific
meeting address an important problem or a critical barrier to progress in the
field? If the aims of the project are achieved, how will scientific
knowledge, technical capability, and/or clinical practice be improved?
How will successful completion of the conference/scientific meeting change the
concepts, methods, technologies, treatments, services, or preventative
interventions that drive this field?

Investigator(s). Are the PDs/PIs, collaborators, and other researchers well suited for
organizing and fulfilling the goals of this conference/scientific
meeting? If Early Stage Investigators or New Investigators, or in the
early stages of independent careers, do they have appropriate experience and
training? If established, have they demonstrated an ongoing record of
accomplishments that have advanced their field(s)? If the project is
collaborative or multi-PD/PI, do the investigators have complementary and
integrated expertise; are their leadership approach, governance and organizational
structure appropriate for the project? Are the key personnel and selected
speakers appropriate and well suited for their described roles in the
conference/scientific meeting?

Innovation. Does
the conference/scientific meeting content challenge and seek to shift current
research or clinical practice paradigms, or employ novel approaches or methods
to fulfill its purpose? Will the conference/scientific meeting cover
concepts, approaches or methodologies, instrumentation, or interventions novel
to one field of research or novel in a broad sense? Will the
conference/scientific meeting address a refinement, improvement, or new
application of theoretical concepts, approaches or methodologies,
instrumentation, or interventions proposed? Does the conference/scientific
meeting draw together appropriate experts who may otherwise not have an
opportunity to meet?

Approach. Are
the format and agenda for the conference/meeting well-reasoned and appropriate
to accomplish the specific aims of the conference/scientific meeting? Are
potential problems, alternative strategies, and benchmarks for success
presented? If the field is in the early stages of development, will the
conference/scientific meeting establish feasibility and will particularly risky
aspects be addressed?
If the project involves clinical research, are the plans for 1) protection of
human subjects from research risks, and 2) inclusion of minorities and members
of both sexes/genders, as well as the inclusion of children, justified in terms
of the scientific goals and research strategy proposed? Is the
conference/meeting timely for the subject matter?

Environment. Will
the conference/scientific meeting site contribute to the probability of
success? Are the institutional support, equipment and other physical
resources available adequate for the conference/meeting proposed? Will
the conference/scientific meeting benefit from unique features of the
scientific environment, subject populations, or collaborative
arrangements?

Additional Review
Criteria

As applicable for the project proposed,
reviewers will consider the following additional
items in the determination of scientific and technical merit, but will not give
separate scores for these items.

Protections
for Human Subjects. For research that involves human subjects but does not involve one
of the six categories of research that are exempt under 45 CFR Part 46, the
committee will evaluate the justification for involvement of human subjects and
the proposed protections from research risk relating to their participation
according to the following five review criteria: 1) risk to subjects, 2)
adequacy of protection against risks, 3) potential benefits to the subjects and
others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring
for clinical trials.

For
research that involves human subjects and meets the criteria for one or
more of the six categories of research that are exempt under 45 CFR Part 46,
the committee will evaluate: 1) the justification for the exemption, 2) human
subjects involvement and characteristics, and 3) sources of materials.

Inclusion
of Women, Minorities, and Children. When the proposed project involves clinical
research, the committee will evaluate the proposed plans for inclusion of
minorities and members of both genders, as well as the inclusion of children.

Vertebrate
Animals.
The committee will evaluate the involvement of live vertebrate animals as part
of the scientific assessment according to the following five points: 1)
proposed use of the animals, and species, strains, ages, sex, and numbers to be
used; 2) justifications for the use of animals and for the appropriateness of
the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures
for limiting discomfort, distress, pain and injury to that which is unavoidable
in the conduct of scientifically sound research including the use of analgesic,
anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and
5) methods of euthanasia and reason for selection if not consistent with the
AVMA Guidelines on Euthanasia. For additional information, see http://grants.nih.gov/grants/olaw/VASchecklist.pdf.

Biohazards. Reviewers will
assess whether materials or procedures proposed are potentially hazardous to
research personnel and/or the environment, and if needed, determine whether
adequate protection is proposed.

Appropriate Representation: How well do the plans for inclusion of women, racial/ethnic minorities, persons
with disabilities, and other individuals who traditionally have
been underrepresented in science provide for their appropriate
representation in the planning, organization, and execution of the proposed
conference/scientific meeting?

Resubmission Applications. When reviewing a Resubmission application (formerly called an amended
application), the committee will evaluate the application as now presented,
taking into consideration the responses to comments from the previous
scientific review group and changes made to the project.

Renewal Applications. When reviewing a Renewal application (formerly called a competing
continuation application), the committee will consider the progress made in the
last funding period.

Revision Applications. When reviewing a Revision application (formerly called a competing
supplement application), the committee will consider the appropriateness of the
proposed expansion of the scope of the project. If the Revision application
relates to a specific line of investigation presented in the original
application that was not recommended for approval by the committee, then the
committee will consider whether the responses to comments from the previous scientific
review group are adequate and whether substantial changes are clearly evident.

Additional Review Considerations

As applicable for the project proposed, reviewers will address each of the
following items, but will not give scores for these items and should not
consider them in providing an overall impact/priority score.

Budget and Period of Support: The reasonableness of the proposed budget and
the appropriateness of the requested period of support in relation to the
proposed research may be assessed by the reviewers.

Selection Process

Applications
submitted in response to this funding opportunity will compete for available
funds with all other recommended applications. The following will be
considered in making funding decisions:

Scientific
and technical merit of the proposed project as determined by scientific
peer review.

After the peer review of the application is
completed, the PD/PI will be able to access his or her Summary Statement
(written critique) via the eRA Commons.

If
the application is under consideration for funding, NIOSH will request
"just-in-time" information from the applicant. HHS grants policies as
described in theHHS Grants
Policy Statement will apply to the applications submitted and awards made
in response to this FOA.

A formal notification in the form of a Notice
of Award (NoA) will be provided to the applicant organization. The NoA signed
by the Grants Management Officer (GMO) is the authorizing document. CDC will
mail and/or e-mail this document to the recipient fiscal officer identified in
the application.

Selection of the application for award is not
an authorization to begin performance. Any cost incurred before receipt of the
NoA is at the recipient’s risk. These costs may be reimbursed only to the
extent considered allowable pre-award costs. See also Section IV.5. Funding Restrictions.

2. Administrative and National Policy Requirements

All CDC/NIOSH grant and cooperative agreement awards
include the HHS Grants Policy Statement as part of the
NoA.The following Terms and Conditions will be
incorporated into the award statement and will be provided to the Principal
Investigator as well as to the appropriate institutional official, at the time
of award.

All conference material (promotional
materials, agenda, publications an internet sites) related to this project must
include an acknowledgement of NIH grant support and a disclaimer stating the
following: “Funding for this conference was made possible [in part] by
[insert grant number] from NIOSH. The views expressed in written
conference materials or publications and by speakers and moderators do not
necessarily reflect the official policies of the Department of Health and Human
Services; nor does mention of trade names, commercial practices, or organizations
imply endorsement by the U.S. Government.”

3. Reporting

Recipient organizations must provide CDC/NIOSH with an original, plus
two hard copies of the following reports:

1) Non-Competing Grant Progress
Report, (use form PHS 2590, posted on the CDC/NIOSH website, and at , no less than 120 days prior to the end of the current
budget period. The progress report will serve as the non-competing continuation
application. The Progress Report should include a report of the previous
meeting supported by the current grant, as well as a full description of the
next planned meeting.

2) Financial status report, no more
than 90 days after the end of the budget period.

3) Final financial and performance
reports, no more than 90 days after the end of the project period.

Recipient organizations
must forward these reports by the U.S. Postal Service or express delivery to
the Grants Management Specialist listed in the “Agency Contacts” section of
this FOA.

Although the financial
plans of NIOSH provide support for this program, awards pursuant to this
funding opportunity are contingent upon the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required reports) and
the determination that continued funding is in the best interest of the Federal
government.

Human
Subjects ProtectionFederal regulations (45 CFR Part 46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and others,
and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm). Additional HHS/CDC
Requirements under AR-1 Human Subjects Requirements can be found on the
Internet at the following address: http://www.cdc.gov/od/pgo/funding/ARs.htm.

Requirements
for Inclusion of Women and Racial and Ethnic Minorities in ResearchIt is
the policy of the Centers for Disease Control and Prevention (CDC) and the
Agency for Toxic Substances and Disease Registry (ATSDR) to ensure that
individuals of both sexes and the various racial and ethnic groups will be
included in CDC/ATSDR-supported research projects involving human subjects,
whenever feasible and appropriate. Racial and ethnic groups are those defined
in OMB Directive No. 15 and include American Indian or Alaska Native, Asian,
Black or African American, Hispanic or Latino, Native Hawaiian or Other Pacific
Islander. Applicants shall ensure that women, racial and ethnic minority
populations are appropriately represented in applications for research
involving human subjects. Where clear and compelling rationale exist that
inclusion is inappropriate or not feasible, this situation must be explained as
part of the application. This policy does not apply to research studies when
the investigator cannot control the race, ethnicity, and/or sex of subjects.
Further guidance to this policy is contained in the Federal Register, Vol. 60,
No. 179, pages 47947-47951, and dated Friday, September 15, 1995.

Inclusion Of Persons Under The Age Of 21 In
Research
The policy of CDC is that persons under the age of 21 must be included in all
human subjects research that is conducted or supported by CDC, unless there are
scientific and ethical reasons not to include them. This policy applies to all
CDC-conducted or CDC-supported research involving human subjects, including
research that is otherwise exempt in accordance with Sections 101(b) and 401(b)
of 45 CFR Part
46, HHS Policy for the Protection of Human Subjects. Therefore, proposals
for research involving human subjects must include a description of plans for
including persons under the age of 21. If persons under the age of 21 will be
excluded from the research, the application or proposal must present an
acceptable justification for the exclusion.

In an extramural research plan, the investigator should
create a section titled "Participation of persons under the age of
21." This section should provide either a description of the plans to
include persons under the age of 21 and a rationale for selecting or excluding
a specific age range, or an explanation of the reason(s) for excluding persons under
the age of 21 as participants in the research. When persons under the age of 21
are included, the plan must also include a description of the expertise of the
investigative team for dealing with individuals at the ages included, the
appropriateness of the available facilities to accommodate the included age
groups, and the inclusion of a sufficient number of persons under the age of 21
to contribute to a meaningful analysis relative to the purpose of the study.
Scientific review groups at CDC will assess each application as being
acceptable or unacceptable in regard to the age-appropriate inclusion or
exclusion of persons under the age of 21 in the research project, in addition
to evaluating the plans for conducting the research in accordance with these
provisions.

The inclusion of children (as defined by the applicable
law of the jurisdiction in which the research will be conducted) as subjects in
research must be in compliance with all applicable subparts of 45 CFR Part
46,
as well as with other pertinent federal laws and regulations.

The policy of inclusion of persons under the age of 21 in
CDC-conducted or CDC-supported research activities in foreign countries
(including collaborative activities) is the same as that for research conducted
in the United States.

HIV/AIDS
Confidentiality Provisions
Recipients must have confidentiality and security
provisions to protect data collected through HIV/AIDS surveillance, including copies
of local data release policies; employee training in confidentiality
provisions; State laws, rules, or regulations pertaining to the protection or
release of surveillance information; and physical security of hard copies and
electronic files containing confidential surveillance information.

Describe
laws, rules, regulations, or health department policies that require or permit
the release of patient-identifying information collected under the HIV/AIDS
surveillance system to entities outside the public health department; describe
also the measures the health department has taken to ensure that persons
reported to the surveillance system are protected from further or unlawful
disclosure.

Some projects may require Institutional Review Board
(IRB) approval or a certificate of confidentiality.

To meet
the requirements for a program review panel, you are encouraged to use an
existing program review panel, such as the one created by the State health
department's HIV/AIDS prevention program. If you form your own program review
panel, at least one member must be an employee (or a designated representative)
of a State or local health department. List the names of the review panel
members on the Assurance of Compliance form, CDC 0.1113. Submit the program
review panel's report that all materials have been approved.

If the proposed project involves hosting a conference,
submit the program review panel's report stating that all materials, including
the proposed conference agenda, have been approved. Submit a copy of the
proposed agenda with the application.

Before funds are used to develop educational materials,
determine whether suitable materials already exist in the CDC National
Prevention Information Network (NPIN). The website can be found at; http://www.nchstp.cdc.gov/od/infocenter/npin.htm.

Patient CareEnsure that all STD or HIV infected patients enrolled
in the proposed project will be linked to an appropriate local care system that
can address their specific needs, such as medical care, counseling, social
services, and therapy.

Public Health System
Reporting RequirementsThis program is subject to the Public Health System
Reporting Requirements. Under these requirements, all community-based
non-governmental organizations submitting health services applications must
prepare and submit the items identified below to the head of the appropriate
State and/or local health agency(s) in the program area(s) that may be impacted
by the proposed project no later than the application deadline date of the
Federal application. The appropriate State and/or local health agency is
determined by the applicant. The following information must be provided:

A. A copy of the face page of the application (SF 424).

B. A summary of the project that should be titled "Public Health
System Impact Statement" (PHSIS), not exceed one page, and include the
following:

1. A
description of the population to be served.

2. A
summary of the services to be provided.

3. A
description of the coordination plans with the appropriate state and/or local
health agencies.

If the State and/or local health official should desire
a copy of the entire application, it may be obtained from the State Single
Point of Contact (SPOC) or directly from the applicant.

Paperwork Reduction Act RequirementsUnder the
Paperwork Reduction Act, projects that involve the collection of information
from 10 or more individuals and funded by a grant or a cooperative agreement
will be subject to review and approval by the Office of Management and Budget
(OMB).

Smoke-Free
Workplace RequirementsHHS/CDC strongly encourages all recipients to provide a
smoke-free workplace and to promote abstinence from all tobacco products.
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities that receive Federal funds in which education, library, day care,
health care, or early childhood development services are provided to children.

Healthy People
2010The Public Health Service (PHS) is committed to
achieving the health promotion and disease prevention objectives of
"Healthy People 2010," a PHS-led national activity for setting
priority areas. This FOA is related to one or more of the priority areas.
Potential applicants may obtain a copy of "Healthy People 2010" at www.healthypeople.gov.

Lobbying RestrictionsApplicants should be aware of restrictions on the use
of HHS funds for lobbying of Federal or State legislative bodies. Under the
provisions of 31 U.S.C. Section 1352, recipients (and their sub-tier
contractors) are prohibited from using appropriated Federal funds (other than
profits from a Federal contract) for lobbying congress or any Federal agency in
connection with the award of a particular contract, grant, cooperative
agreement, or loan. This includes grants/cooperative agreements that, in whole
or in part, involve conferences for which Federal funds cannot be used directly
or indirectly to encourage participants to lobby or to instruct participants on
how to lobby.

In
addition no part of HHS/CDC appropriated funds, shall be used, other than for
normal and recognized executive-legislative relationships, for publicity or
propaganda purposes, for the preparation, distribution, or use of any kit,
pamphlet, booklet, publication, radio, television, or video presentation
designed to support or defeat legislation pending before the Congress or any
State or local legislature, except in presentation to the Congress or any State
or local legislature itself. No part of the appropriated funds shall be used to
pay the salary or expenses of any grant or contract recipient, or agent acting
for such recipient, related to any activity designed to influence legislation
or appropriations pending before the Congress or any State or local
legislature.

Any activity designed to influence action in regard to
a particular piece of pending legislation would be considered
"lobbying." That is lobbying for or against pending legislation, as
well as indirect or "grass roots" lobbying efforts by award
recipients that are directed at inducing members of the public to contact their
elected representatives at the Federal or State levels to urge support of, or
opposition to, pending legislative proposals is prohibited. As a matter of
policy, HHS/CDC extends the prohibitions to lobbying with respect to local
legislation and local legislative bodies.

The provisions are not intended to prohibit all
interaction with the legislative branch, or to prohibit educational efforts
pertaining to public health. Clearly there are circumstances when it is
advisable and permissible to provide information to the legislative branch in
order to foster implementation of prevention strategies to promote public
health. However, it would not be permissible to influence, directly or
indirectly, a specific piece of pending legislation

It remains permissible to use HHS/CDC funds to engage
in activity to enhance prevention; collect and analyze data; publish and
disseminate results of research and surveillance data; implement prevention
strategies; conduct community outreach services; provide leadership and
training, and foster safe and healthful environments.

Recipients of HHS/CDC grants and cooperative agreements
need to be careful to prevent HHS/CDC funds from being used to influence or
promote pending legislation. With respect to conferences, public events,
publications, and "grassroots" activities that relate to specific
legislation, recipients of HHS/CDC funds should give close attention to
isolating and separating the appropriate use of HHS/CDC funds from non-CDC
funds. HHS/CDC also cautions recipients of HHS/CDC funds to be careful not to
give the appearance that HHS/CDC funds are being used to carry out activities
in a manner that is prohibited under Federal law.

Prohibition
on Use of HHS/CDC Funds for Certain Gun Control Activities
The Departments of Labor, Health and Human Services,
and Education, and Related Agencies Appropriations Act specifies that:
"None of the funds made available for injury prevention and control at the
Centers for Disease Control and Prevention may be used to advocate or promote
gun control."

Anti-Lobbying Act requirements prohibit lobbying
Congress with appropriated Federal monies. Specifically, this Act prohibits the
use of Federal funds for direct or indirect communications intended or designed
to influence a member of Congress with regard to specific Federal legislation.
This prohibition includes the funding and assistance of public grassroots
campaigns intended or designed to influence members of Congress with regard to
specific legislation or appropriation by Congress.

In addition to the restrictions in the Anti-Lobbying
Act, HHS/CDC interprets the language in the HHS/CDC's Appropriations Act to
mean that HHS/CDC's funds may not be spent on political action or other
activities designed to affect the passage of specific Federal, State, or local
legislation intended to restrict or control the purchase or use of firearms.

Accounting
System RequirementsThe services of a certified public accountant licensed
by the State Board of Accountancy or the equivalent must be retained throughout
the project as a part of the recipient's staff or as a consultant to the
recipient's accounting personnel. These services may include the design,
implementation, and maintenance of an accounting system that will record
receipts and expenditures of Federal funds in accordance with accounting
principles, Federal regulations, and terms of the cooperative agreement or
grant.

Capability AssessmentIt may be necessary to conduct an on-site evaluation of
some applicant organization's financial management capabilities prior to or
immediately following the award of the grant or cooperative agreement.
Independent audit statements from a Certified Public Accountant (CPA) for the
preceding two fiscal years may also be required.

Proof
of Non-profit StatusProof of nonprofit status must be submitted by private
nonprofit organizations with the application. Any of the following is
acceptable evidence of nonprofit status: (a) a reference to the applicant organization's
listing in the Internal Revenue Service's (IRS) most recent list of tax-exempt
organizations described in section 501(c)(3) of the IRS Code; (b) a copy of a
currently valid IRS tax exemption certificate; (c) a statement from a State
taxing body, State Attorney General, or other appropriate State Official
certifying that the applicant organization has a nonprofit status and that none
of the net earnings accrue to any private shareholders or individuals; (d) a
certified copy of the organization's certificate of incorporation or similar
document that clearly establishes nonprofit status; (e) any of the above proof
for a State or national parent organization and a statement signed by the
parent organization that the applicant organization is a local nonprofit
affiliate.

Security Clearance RequirementAll individuals who will be performing work under a
grant or cooperative agreement in a HHS/CDC-owned or leased facility (on-site
facility) must receive a favorable security clearance, and meet all security
requirements. This means that all awardees employees, fellows, visiting
researchers, interns, etc., no matter the duration of their stay at HHS/CDC
must undergo a security clearance process.

Research Integrity
The signature of the institution official on
the face page of the application submitted under this Funding Opportunity
Announcement is certifying compliance with the Department of Health and Human
Services (DHHS) regulations in Title 42 Part 93, Subparts A-E, entitled PUBLIC
HEALTH SERVICE POLICIES ON RESEARCH MISCONDUCT.

Section 93.301 Institutional assurances. (a)
General policy. An institution with PHS supported biomedical or behavioral
research, research training or activities related to that research or research
training must provide PHS with an assurance of compliance with this part,
satisfactory to the Secretary. PHS funding components may authorize [[Page
28389]] funds for biomedical and behavioral research, research training, or
activities related to that research or research training only to institutions
that have approved assurances and required renewals on file with ORI. (b)
Institutional Assurance. The responsible institutional official must assure on
behalf of the institution that the institution-- (1) Has written policies and
procedures in compliance with this part for inquiring into and investigating
allegations of research misconduct; and (2) Complies with its own policies and
procedures and the requirements of this part.

Compliance
with Executive Order 13279Faith-based
organization are eligible to receive federal financial assistance, and their
applications are evaluated in the same manner and using the same criteria as
those for non-faith-based organizations in accordance with Executive Order
13279, Equal Protection of the Laws for Faith-Based and Community Organizations.
All applicants should, however, be aware of restrictions on the use of direct
financial assistance from the Department of Health and Human Services (DHHS)
for inherently religious activities. Under the provisions of Title 45, Parts
74, 87, 92 and 96, organizations that receive direct financial assistance from
DHHS under any DHHS program may not engage in inherently religious activities,
such as worship, religious instruction, or proselytization as a part of the
programs or services funded with direct financial assistance from DHHS. If an
organization engages in such activities, it must offer them separately, in time
or location, from the programs or services funded with direct DHHS assistance,
and participation must be voluntary for the beneficiaries of the programs or
services funded with such assistance. A religious organization that
participates in the DHHS funded programs or services will retain its
independence from Federal, State, and local governments, and may continue to
carry out its mission, including the definition, practice, and expression of
its religious beliefs, provided that it does not use direct financial
assistance from DHHS to support inherently religious activities such as those
activities described above. A faith-based organization may, however, use space
in its facilities to provide programs or services funded with financial
assistance from DHHS without removing religious art, icons, scriptures, or
other religious symbols. In addition, a religious organization that receives
financial assistance from DHHS retains its authority over its internal
governance, and it may retain religious terms in its organization=s name, select its board members on a
religious basis, and include religious references in its organization=s mission statements and other
governing documents in accordance with all program requirements, statutes, and
other applicable requirements governing the conduct of DHHS funded activities. For
further guidance on the use of DHHS direct financial assistance see Title 45,
Code of Federal Regulations, Part 87, Equal Treatment for Faith-Based
Organizations, and visit the internet site:http://www.whitehouse.gov/government/fbci/

Health Insurance Portability and Accountability Act
RequirementsRecipients of this grant award should note that
pursuant to the Standards for Privacy of Individually Identifiable Health
Information promulgated under the Health Insurance Portability and
Accountability Act (HIPAA) (45 CFR Parts 160 and 164) covered entities may
disclose protected health information to public health authorities authorized
by law to collect or receive such information for the purpose of preventing or
controlling disease, injury, or disability, including, but not limited to, the
reporting of disease, injury, vital events such as birth or death, and the
conduct of public health surveillance, public health investigations, and public
health interventions. The definition of a public health authority includes a
person or entity acting under a grant of authority from or contract with such
public agency. HHS/CDC considers this project a public health activity
consistent with the Standards for Privacy of Individually Identifiable Health
Information and HHS/CDC will provide successful recipients a specific grant of
public health authority for the purposes of this project.

Release and Sharing of DataThe Data Release Plan is the Grantee's assurance that
the dissemination of any and all data collected under the HHS/CDC data sharing
agreement will be released as follows:

a. In
a timely manner.

b. Completely,
and as accurately as possible.

c. To
facilitate the broader community.

d. Developed
in accordance with HHS/CDC policy on Releasing and Sharing Data.

Applications must
include a copy of the applicant's Data Release Plan. Applicants should provide
HHS/CDC with appropriate documentation on the reliability of the data.
Applications submitted without the required Plan may be ineligible for award.
Award will be made when reviewing officials have approved an acceptable Plan.
The successful applicant and the Program Manager will determine the
documentation format. HHS/CDC recommends data is released in the form closest
to micro data and one that will preserve confidentiality.

National Historic Preservation Act of 1966

(Public Law 89-665, 80 Stat. 915)

The grantee’s signature on the grant
application attests to their: (1) knowledge of the National Historic
Preservation Act of 1966 (Public Law 89-665, 80 Stat. 915); and (2) intent to
ensure all grant related activities are in compliance with referenced public
law, as stated:

The head of any
Federal agency, having direct or indirect jurisdiction over a proposed Federal
or Federally assisted undertaking in any State and the head of any Federal
department or independent state agency having authority to license any
undertaking, shall, prior to the approval of the expenditure of any Federal
funds on the undertaking or prior to the issuance of any license, as the case
may be, take into account the effect of the undertaking on any district, site,
building, structure, or object that is included in or is eligible for inclusion
in the National Register. The head of any such Federal agency shall afford the
Advisory Council on Historic Preservation established under Title II of this
ACT a reasonable opportunity to comment with regard to such undertaking.

b. Additionally, the NHPA also contains the following
excerpt that forbids “anticipatory demolition:”

Each Federal
agency shall ensure that the agency will not grant a loan, loan guarantee,
permit, license, or other assistance to an applicant who, with intent to avoid
the requirements of Section 106 of this Act, has intentionally, significantly,
adversely affected a historic property to which the grant would relate or,
having legal power to prevent it, allowed such significant adverse effect to
occur, unless the agency, after consultation with the Council, determines that
circumstances justify granting such assistance despite the adverse effect
created or permitted by the applicant.

Conference
Disclaimer and Use of Logos

Disclaimer: Where a conference is funded by a
grant or cooperative agreement, a sub grant or a contract the recipient must
include the following statement on conference materials, including promotional
materials, agenda, and internet sites:

“Funding for this conference was made
possible [in part] by [insert grant or cooperative agreement award number] from
the Centers for Disease Control and Prevention(CDC) or the Agency for Toxic
Substances and Disease Registry (ATSDR) . The views expressed in written
conference materials or publications and by speakers and moderators do not
necessarily reflect the official policies of the Department of Health and Human
Services; nor does mention of trade names, commercial practices, or
organizations imply endorsement by the U.S. Government.”

Logos: Neither the HHS nor the CDC (“CDC” includes
ATSDR) logo may be displayed if such display would cause confusion as to the
source of the conference or give the false appearance of Government
endorsement. A non-federal entity’s unauthorized use of the HHS name or logo is
governed by U.S.C. § 1320b-10, which prohibits the misuse of the HHS name and
emblem in written communication. The appropriate use of the HHS logo is subject
to the review and approval of the Office of the Assistant Secretary for Public
Affairs (OASPA). Moreover, the Office of the Inspector General has authority to
impose civil monetary penalties for violations (42 C.F.R. Part 1003). Neither
the HHS nor the CDC logo can be used on conference materials under a grant,
cooperative agreement, contract or co-sponsorship agreement without the
expressed, written consent of either the Project Officer or the Grants
Management Officer. It is the responsibility of the grantee (or recipient of
funds under a cooperative agreement) to request consent for the use of the logo
in sufficient detail to assure a complete depiction and disclosure of all uses
of the Government logos, and to assure that in all cases of the use of
Government logos, the written consent of either the Project Officer or the
Grants Management Officer has been received.